Skip to main contentSkip to footer

Targeting the Root Cause of Autoimmune Disease

Breakthrough Therapy in Autoimmunity

  • si-544 – First-in-Class Kv1.3 Blocker

  • First disease modifying treatment for T cell autoimmunity

Autoimmunity affects millions worldwide, but current treatments leave the root cause untouched. si-544 is the first therapy to safely and selectively deactivate disease-causing T cells, while preserving immune competence.
MECHANISM OF ACTION
CLINICAL TRIALS
Selection Therapeutics Mountains Hiker

THE CHALLENGE

Autoimmunity is an everyday burden people carry for life

Today’s treatments rely on broad immunosuppression to manage symptoms, yet leave the root cause of disease untouched. Patients deserve durable disease modification.

THE SCIENCE

Precision targeting of disease-driving T cells

si-544 represents a transformational breakthrough by precisely targeting Kv1.3, a potassium channel that only disease-driving T cells are dependent on. si-544 selectively blocks Kv1.3 and stops the activation and proliferation of autoreactive T cells while maintaining healthy immune cells.

THE POTENTIAL

Delivering life-changing impact for patients

si-544 goes beyond symptom control and has the potential to be the first treatment in T cell-mediated autoimmunity to deliver durable disease modification. As a safe, selective Kv1.3 blocker, si-544 could redefine treatment across 80+ indications.

THE CHALLENGE

Autoimmunity is inadequately addressed

1M
people affected in the U.S. 1
5–0%
affected globally 2
$0B+
for healthcare costs in the US 3

Sources: 1) Autoimmune Association, 2) Global Autoimmune Institute, 3) National Institutes of Health (NIH)

Autoimmunity is an everyday
burden people carry for life.

  • A lifetime of treatment, follow-up visits and tests
  • Serious risks due to immunosuppression under therapy
  • Potential for multiple autoimmunities to present
  • Significant toll on mental health and financial well-being
  • Symptomatic treatments have no significant impact on lifelong disease burden
MORE ABOUT AUTOIMMUNITY

THE SCIENCE

Precision targeting of disease-driving T cells

The development of
si-544 is a transformational breakthrough

First safe and effective Kv1.3 blocker in 40+ years of research

Highly selective and broadly applicable

si-544 – Selective. Precise. Disease-Modifying.

si-544 represents a transformational breakthrough by precisely targeting Kv1.3, a potassium channel that only disease-driving T cells are dependent on. si-544 selectively blocks Kv1.3 and stops the activation and proliferation of autoreactive T cells while maintaining healthy immune cells. By targeting only autoreactive T cells, it has the potential to restore immune system balance and normal function.
Because Kv1.3 dependency is shared across key autoreactive T cell-mediated diseases, si-544 has broad therapeutic potential across a wide range of autoimmune conditions, including psoriasis, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and many others.
MECHANISM OF ACTION
selectION si-544

THE POTENTIAL

si-544 has demonstrated safety and promising efficacy in clinical trials

Safe & Well Tolerated

Immune Integrity Preserved

Efficacy and durable results

si-544 – A potential systemic first-line autoimmunity treatment that delivers life-changing impact for patients

  • First Kv1.3 blocker proven safe in humans
  • Precision targeting of autoreactive T cells only
  • Short treatment cycles, long-term relief
  • Pipeline-in-a-product opportunity
PIPELINE
CLINICAL TRIALS

News & Events

All News & Events

“si-544 has the potential to become a disease modifying and safe treatment option, offering meaningful and durable reduction of disease burden across a broad spectrum of T cell-mediated autoimmune diseases.”

Antonius Schuh | CEO
selectION, Inc.